Using CDs in enantioseparation is rather straightforward. On an analytical level. However, preparation is a completely different question. Potential solutions for this problem and the impact of CD types are explored in the study of Zhejiang University of Technology and Jiaxing University,discussing applications in CPC and liquid-liquid extraction.
We welcome growing interest in combining carbohydrates with other drug delivery systems to improve performance. Locate Bio Ltd (Helen Cox, Kevin Shakesheff, and Charles Matthews) creates osteoconductive medical implants using PLGA, Ca phosphate, cyclodextrin and poloxamer.
Fascinating news from Beren Therapeutics: Beren Awarded Expedited Roadmap for Treatment of Homozygous Familial Hypercholesterolemia Beren’s novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP), for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia. The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases. “We are excited to begin work under ILAP and look forward to collaborating with other regulators, payors, and governments to expedite the development and identify and remove access barriers.” – commented Jason Camm, CEO. Jules Payne from HEART UK – The Cholesterol Charity added that “Significant unmet needs remain, and with this advancement, we are hopeful for a new treatment option that can truly alter the course of the disease for the children and patients living with HoFH.” Beren Therapeutics, P.B.C. is currently in stealth.
Using CDs to formulate proteins, dominantly to prevent aggregation is more or less known; there are CDs marketed for such uses (Roquette – Kleptose Biopharma) still, no product is on the market. This patent from Genentech (Brian Connolly; Lydia Hamburg; Emily Holz) proposes another feature: when using CDs with monoclonal antibodies, degradation of polysorbates is also reduced.
If you even used CDs, you probably are familiar with SBECD. In this review, there is a nice colleaction of this parenteral excipient’s current and potential future applications.
What is the future of cyclodextrin: excipient or API? A very timely review from University of Debrecen (Gyorgy Panyi, Florina Zakany, et al.) discussing #molecular targets, mechanism of action, and ongoing research in several diseases. Which do you think holds the future?
Two birds with one stone: This study of the Silesian University of Technology and the Polish Academy of Sciences is close to our hearts as we both deal with glycoconjugates and cyclodextrin. They show the delivery of 8-Hydroxyquinoline Glycoconjugates and Doxorubicin using ACD-based hydrogel for enhanced tumor treatment.
I have spent several years studying the chiral recognition of CDs and always considered that selectivity is unpredictable and needs to be tested. In the paper of Jenderal Soedirman University (Ainaya Halwa Lathufa, Uyi Sulaeman, et al.) and Hassan Aboul-Enein enatioseparation of miconazole with molecular docking is predicted using CD derivatives such as sulfated-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, and hydroxypropyl-γ-cyclodextrin as chiral selectors.
The problem is that all these CDs are composites consisting of hundreds of different specific molecules, which makes proper modeling, so to say, “challenging.” But what do you think?
